BioInvent International AB (publ) (LON:0H22)

Market Cap	143.14M +5.2%
Revenue (ttm)	19.33M +533.7%
Net Income	-25.58M
EPS	-0.39
Shares Out	n/a
PE Ratio	n/a
Forward PE	9.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	220
Average Volume	945
Open	44.54
Previous Close	44.54
Day's Range	44.54 - 44.54
52-Week Range	23.30 - 44.54
Beta	-0.03
RSI	33.65
Earnings Date	Feb 26, 2026

About LON:0H22

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-19...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 124
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0H22

Financial Performance

In 2024, LON:0H22's revenue was 44.69 million, a decrease of -37.47% compared to the previous year's 71.46 million. Losses were -429.38 million, 30.0% more than in 2023.

Financial numbers in SEK